*Optimal dilutions/concentrations should be determined by the researcher.
Not tested in other applications.
293T , A431 , H1299 , HeLa , Molt-4 , Raji
0.1M Tris, 0.1M Glycine, 10% Glycerol (pH7). 0.01% Thimerosal was added as a preservative.
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
1 mg/ml (Please refer to the vial label for the specific concentration.)
Carrier-protein conjugated synthetic peptide encompassing a sequence within the C-terminus region of human C5L2. The exact sequence is proprietary.
Purified by antigen-affinity chromatography.
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
complement component 5a receptor 2 , C5L2 , GPF77 , GPR77
The anaphylatoxins C3a (see MIM 120700), C4a (see MIM 120810), and C5a are cationic fragments generated during the complement cascade that participate in host defense. In the case of inappropriate complement activation, anaphylatoxins may be involved in autoimmunity and sepsis. C5L2 is coexpressed with the C5a receptor, C5AR (C5R1; MIM 113995), on polymorphonuclear neutrophils and may modulate C5AR activity (Gerard et al., 2005 [PubMed 16204243]).[supplied by OMIM]